NEW YORK ( TheStreet) -- Exelixis (EXEL) is expecting to hear from the FDA about an approval decision for its medullary thyroid cancer drug cabozantinib by Nov. 29. The Exelixis trade I posted several weeks ago postulated that the shares would trade around $5 before the FDA approval decision date and thus far that's been correct. The trade has been a winner on a percentage basis.
Now that December options are available, there are new ways to trade the upcoming cabaozantinib catalyst. (November options expire before Nov. 29 so the focus now shifts to December expiration options.) Here's the new Exelixis options trade:
Buy 10 DEC 4.0 strike Puts @ 0.35 = $350
Buy 10 DEC 5.0 strike Calls @ 0.60 = $600
Initial Trade P&L = $950 Debit
This is a bullish DEC 4/5 strangle with a total risk of $950 should Exelixis trade between $4 and $5 by expiration. Regardless of stock price direction, I expect (implied) volatility to increase substantially from current levels -- from 95 to 180 (feel free to ridicule me if I am wrong.)This expected increase in volatility should by itself provide 10-20% upside in the premium by the FDA decision date -- thus there is some embedded optionality in the trade structure should I decide to exit the trade the day prior to Nov. 29. If I hold through that date, I need the stock to increase or decrease by 95 cents above or below the $5 strike Call or the $4 strike Put. Thus, the trade's breakeven points are $5.95 or $3.05 by DEC expiration on Dec. 22. Pelz has no position in Exelixis. To learn more about using options to trade biotech stocks, check out Tony Pelz's book, The Biotech Trader Handbook or subscribe to Chimera Research Group.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV